Key clinical point: Hepatectomy offers greater survival benefits than sorafenib therapy in patients with advanced hepatocellular carcinoma (HCC) and macroscopic portal vein tumor thrombus (PVTT).
Major finding: Patients who underwent hepatectomy vs received sorafenib had a significantly longer median survival time (15.1 vs 4.5 months; hazard ratio 1.704; P = .0446).
Study details: This study propensity score-matched patients with advanced HCC and macroscopic PVTT invaded into an ipsilateral first-order portal branch or main trunk/contralateral portal vein who underwent hepatectomy (n = 36) with those who received sorafenib (n = 36).
Disclosures: No source of funding was reported. Some authors reported receiving grants or personal fees from various sources.
Source: Komatsu S et al. Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A bi-institutional propensity-matched cohort study. J Hepatobiliary Pancreat Sci. 2022 (Sep 1). Doi: 10.1002/jhbp.1236
